CAI
Caris Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.98
−3.04%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- $0.03
- Revenue estimate
- $256.3M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$0.00
- EPS estimate
- $0.01
- Revenue actual
- $263.7M
- Revenue estimate
- $238.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -566.7%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $29
- PT range
- $26 – $33
- Analysts
- 3
2 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | $0.01 | -$0.00 | Miss -139.18% | $263.7M |
| May 7, 2026 | -$0.02 | -$0.00 | Beat 92.53% | $216.2M |
| Feb 26, 2026 | $0.01 | -$0.23 | Miss -2420.00% | $292.9M |
| Nov 5, 2025 | -$0.08 | $0.08 | Beat 200.00% | $216.8M |
| Aug 12, 2025 | -$0.21 | -$0.54 | Miss -157.14% | $181.4M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026